Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology company engaged in the production of synthetic DNA through a new enzymatic process, owned by the company, that addresses the needs of advanced therapies where DNA is the fundamental starting material. This is the case of gene therapy and mRNA-based vaccines, emerging therapeutic strategies where manufacturing is an...Read more
With the new investment fund, the managers plan to build two new plants in San Sebastian Columbus Venture Partners already has its second fund ready to invest in companies related to health sciences. It is in the registration phase at the National Securities Market Commission (CNMV) and will be operational shortly. The expected volume is 70 million euros, reports Expansión. According to...Read more
Latest innovations and first-hand business models
The SPRI Group's Net-Zero Basque Industrial SuperCluster initiative has unveiled the roadmap for the decarbonisation of the Basque paper sector by 2050. Along with steelmaking, smelting, cement and refinery, this industry is among the 5 that account for nearly 68% of the greenhouse gas (GHG) emissions in the Basque Country. The report concludes that the transition towards net-zero emissions of the sector will benefit from the development of technological measures focused mainly on energy...Read more
